A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (NCT05303467)
FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
🩺 Plain-English Summary (8th-Grade Level)
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of Alabama Birmingham — Birmingham, Alabama
- University of California San Diego — San Diego, California
- University of California San Francisco — San Francisco, California
- Mayo Jacksonville — Jacksonville, Florida
- Northwestern Univerity — Chicago, Illinois
- Johns Hopkins Interventional Radiology Center — Baltimore, Maryland
- Washington University School of Medicine — St Louis, Missouri
- Lenox Hill Hospital — New York, New York
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (952) 201-3102
Email: Sally.Linda@bsci.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma Multiforme
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme — Iowa City, Iowa
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) — Baltimore, Maryland
- Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme — Washington D.C., District of Columbia
- A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM — Tucson, Arizona
- Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients — Phoenix, Arizona
- Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM — Stanford, California
Explore by condition: All Glioblastoma Multiforme clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.